Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Prostate cancer

Prudent practice optimizes screening outcomes

Nature Reviews Urology volume 13, pages 376–377 (2016)Cite this article

Subjects

Two large prostate screening trials showed apparently conflicting results, providing evidence for both mortality reduction and absence thereof. A modelling study has now assessed the effect of referral and treatment patterns on cost-effectiveness of PSA screening, which might shed further light on the issue by expanding the available empirical data.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Schröder, F. H. et al. ERSPC Investigators. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet. 384, 2027–2035 (2014).

    Article  PubMed Central  Google Scholar 

  2. Andriole, G. L. et al. PLCO Project Team. Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. J. Natl Cancer Inst. 104, 125–132 (2012).

    Article  PubMed Central  Google Scholar 

  3. Gulati, R. et al. The impact of PLCO control arm contamination on perceived PSA screening efficacy. Cancer Causes Control 23, 827–883 (2012).

    Article  PubMed Central  Google Scholar 

  4. Palma, A., Lounsbury, D. W., Schlecht, N. F. & Agalliu, I. A system dynamics modelling of serum prostate-specific antigen screening for prostate cancer. Am. J. Epidemiol. 183, 227–223 (2015).

    Article  PubMed Central  Google Scholar 

  5. Roth, J. A. et al. Economic analysis of prostate-specific antigen screening and selective treatment strategies. JAMA Oncol. http://dx.doi.org/10.1001/jamaoncol.2015.6275 (2016).

  6. Gulati, R., Gore, J. L. & Etzioni, R. Comparative effectiveness of alternative prostate-specific antigen-based prostate cancer screening strategies. Ann. Intern. Med. 158, 145–115 (2013).

    Article  PubMed Central  Google Scholar 

  7. Heijnsdijk, E. et al. Cost-effectiveness of prostate cancer screening. J. Natl Cancer Inst. 107, 36 (2014).

    Google Scholar 

  8. Pataky, R. et al. Is prostate cancer screening cost-effective? Int. J. Cancer 135, 939–994 (2014).

    Article  CAS  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Anssi Auvinen is at the Department of Epidemiology, School of Health Sciences, T-RAK E224 University of Tampere, Medisiinarinkatu 3, FI-33014, Tampere, Finland.,

    Anssi Auvinen

Authors
  1. Anssi Auvinen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Anssi Auvinen.

Ethics declarations

Competing interests

A.A. declares that he has acted as a paid consultant for EPID Research, and has received lecture fees from MSD.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Auvinen, A. Prudent practice optimizes screening outcomes. Nat Rev Urol 13, 376–377 (2016). https://doi.org/10.1038/nrurol.2016.90

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrurol.2016.90

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer